ABUS:NSD-Arbutus Biopharma Corporation (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 2.17

Change

0.00 (0.00)%

Market Cap

USD 0.15B

Volume

0.44M

Average Target Price

USD 6.17 (+184.18%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Arbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of AB-836, a capsid inhibitor that has the potential to inhibit HBV replication by preventing the assembly of functional viral capsids; and AB-423, which is in pre-clinical studies. The company also develops RNAi drugs, which utilize the RNA interference pathway, allows for a novel approach to treating disease. Its RNAi HBV candidates are designed to reduce hepatitis B surface antigen expression in patients chronically infected with HBV. In addition, it develops AB-729, a second generation RNAi therapeutic targeted to hepatocytes; HBV RNA destabilizer, an orally active agent that cause the destabilization of HBV RNAs, which leads to RNA degradation and to reduction in HBsAg levels. Further, the company engages conducting a Phase 1a/1b clinical trial and several pre-clinical and investigational new drug-enabling studies to evaluate proprietary HBV therapeutic agents, together with standard of care therapies, and in combination with each other. It has strategic alliance, licensing, and research collaboration agreements with Marqibo; Gritstone Oncology, Inc.; and Acuitas Therapeutics, Inc. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-05-31 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

N/A

USD74.66B 46.19 34.50
REGN Regeneron Pharmaceuticals, Inc

N/A

USD68.95B 27.40 20.77
SGEN Seattle Genetics, Inc

N/A

USD27.21B N/A N/A
ALXN Alexion Pharmaceuticals, Inc

N/A

USD26.48B 9.58 8.24
MRNA Moderna, Inc

N/A

USD22.83B N/A N/A
INCY Incyte Corporation

N/A

USD22.15B 47.64 35.20
GMAB Genmab A/S

N/A

USD19.60B 56.47 5.78
BMRN BioMarin Pharmaceutical Inc

N/A

USD19.27B 167.62 100.56
ALNY Alnylam Pharmaceuticals, Inc

N/A

USD15.53B N/A N/A
GLPG Galapagos NV

N/A

USD13.41B 70.58 37.88

ETFs Containing ABUS

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -21.94% 28% F 39% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -21.94% 28% F 39% F
Trailing 12 Months  
Capital Gain 19.23% 58% F 76% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 19.23% 58% F 76% C
Trailing 5 Years  
Capital Gain -84.11% 29% F 12% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -84.11% 28% F 11% F
Average Annual (5 Year Horizon)  
Capital Gain -3.08% 44% F 23% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -3.08% 43% F 22% F
Risk Return Profile  
Volatility (Standard Deviation) 69.08% 25% F 12% F
Risk Adjusted Return -4.47% 50% F 29% F
Market Capitalization 0.15B 38% F 41% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio N/A N/A N/A N/A N/A
Price / Cash Flow Ratio -2.11 29% F 68% D+
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -113.44% 27% F 12% F
Return on Invested Capital -43.00% 70% C- 21% F
Return on Assets -25.76% 58% F 17% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 0.50 82% B- 83% B
Short Percent 0.84% 86% B 77% C+
Beta 2.58 9% F 6% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector